Safety of Nasal Influenza Immunisation in Children With Asthma - The SNIFFLE-4 Study
Latest Information Update: 30 Dec 2019
Price :
$35 *
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms SNIFFLE-4
- 18 Dec 2019 Primary endpoint (Change in asthma symptoms and control pre and 4 weeks post LAIV, as assessed by validated questionnaire) has not been met published in the Journal of Allergy and Clinical Immunology
- 18 Dec 2019 Results assessing the safety of LAIV in children with moderate-severe asthma published in the Journal of Allergy and Clinical Immunology
- 02 Mar 2017 Status changed to completed.